Zurnai® (nalmefene injection)
Approval Date: Aug 2024
Note: New Product
An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.
Rezenopy (naloxone hydrochloride) nasal spray
Approval Date: Apr 2024
Note: New Product
Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression
RiVive™ (naloxone hydrochloride) nasal spray
Approval Date: Jul 2023
Note: New Product
Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA
Opvee® (nalmefene hydrochloride) nasal spray
Approval Date: May 2023
Note: New Product
Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use
